June 3, 2024 Average drug sales 0 Comments Time is money in drug development – Healthcare Economist Delays in drug approvals cost pharmaceutical firms money. These costs include both lost sales as well as additional cost if clinical trials need to ... Read More
April 23, 2024 CER 0 Comments Do patients value improvements in progression-free survival? – Healthcare Economist Progression-free survival (PFS) is a surrogate endpoint is defined as follows (by ChatGPT): In essence, PFS refers to the length of time during a ... Read More